Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic Malignancies

NCT06191887 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06191887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06191887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic Malignancies
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
March 18, 2024
Completion date
December 31, 2040
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma, recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, recurrent transformed chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory small lymphocytic lymphoma, refractory transformed chronic lymphocytic leukemia